ZA918712B - Pharmaceutical product comprising an antibody to tnf or a tnf binding fragment thereof and a xanthine derivative - Google Patents

Pharmaceutical product comprising an antibody to tnf or a tnf binding fragment thereof and a xanthine derivative

Info

Publication number
ZA918712B
ZA918712B ZA918712A ZA918712A ZA918712B ZA 918712 B ZA918712 B ZA 918712B ZA 918712 A ZA918712 A ZA 918712A ZA 918712 A ZA918712 A ZA 918712A ZA 918712 B ZA918712 B ZA 918712B
Authority
ZA
South Africa
Prior art keywords
tnf
antibody
xanthine derivative
xanthine
range
Prior art date
Application number
ZA918712A
Other languages
English (en)
Inventor
Hiristo Anagnostopulos
Ulrich Gebert
Heinz Hanel
Michael Limbert
Mark William Bodmer
Gerald Anthony Higgs
Original Assignee
Celltech Ltd
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltech Ltd, Hoechst Ag filed Critical Celltech Ltd
Publication of ZA918712B publication Critical patent/ZA918712B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA918712A 1990-11-01 1991-11-01 Pharmaceutical product comprising an antibody to tnf or a tnf binding fragment thereof and a xanthine derivative ZA918712B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909023783A GB9023783D0 (en) 1990-11-01 1990-11-01 Pharmaceutical product

Publications (1)

Publication Number Publication Date
ZA918712B true ZA918712B (en) 1992-09-30

Family

ID=10684716

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA918712A ZA918712B (en) 1990-11-01 1991-11-01 Pharmaceutical product comprising an antibody to tnf or a tnf binding fragment thereof and a xanthine derivative

Country Status (15)

Country Link
EP (1) EP0564461B1 (fr)
JP (1) JP3468515B2 (fr)
KR (1) KR930701970A (fr)
AT (1) ATE146971T1 (fr)
AU (1) AU653180B2 (fr)
CA (1) CA2094154A1 (fr)
DE (1) DE69123984T2 (fr)
DK (1) DK0564461T3 (fr)
ES (1) ES2096662T3 (fr)
GB (1) GB9023783D0 (fr)
GR (1) GR3022210T3 (fr)
HU (1) HUT70267A (fr)
NO (1) NO931580D0 (fr)
WO (1) WO1992007585A1 (fr)
ZA (1) ZA918712B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
AU5152293A (en) * 1992-10-08 1994-05-09 Kennedy Institute Of Rheumatology, The Treatment of autoimmune and inflammatory disorders
US6770279B1 (en) 1992-10-08 2004-08-03 The Kennedy Institute Of Rheumatology TNFα antagonists and cyclosporin in therapy of rheumatoid arthritis
RU2139092C1 (ru) 1993-06-03 1999-10-10 Терапьютик Антибодиз Инк. Фрагменты антител в терапии
AU1090795A (en) * 1993-11-12 1995-05-29 Cell Therapeutics, Inc. Method for preventing tissue injury from hypoxia
DE4411660A1 (de) * 1994-04-05 1995-10-12 Hoechst Ag Verwendung von Xanthinderivaten zur Reduktion der pathologischen Hyperreagibilität eosinophiler Granulozyten, neue Xanthinverbindungen und Verfahren zu deren Herstellung
AU5696198A (en) * 1996-12-06 1998-06-29 Amgen, Inc. Combination therapy using a tnf binding protein for treating tnf-mediated diseases
SI0942740T1 (en) * 1996-12-06 2003-12-31 Amgen Inc. Combination therapy using a tnf binding protein for treating tnf-mediated diseases
US6294350B1 (en) * 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
US6395273B1 (en) * 1998-06-10 2002-05-28 Promega Corporation Prevention and treatment of inflammatory bowel disease

Also Published As

Publication number Publication date
EP0564461A1 (fr) 1993-10-13
AU653180B2 (en) 1994-09-22
EP0564461B1 (fr) 1997-01-02
HU9301093D0 (en) 1993-07-28
DE69123984D1 (de) 1997-02-13
DE69123984T2 (de) 1997-05-22
JP3468515B2 (ja) 2003-11-17
CA2094154A1 (fr) 1992-05-02
DK0564461T3 (da) 1997-01-20
JPH06502629A (ja) 1994-03-24
HUT70267A (en) 1995-09-28
WO1992007585A1 (fr) 1992-05-14
ES2096662T3 (es) 1997-03-16
GB9023783D0 (en) 1990-12-12
KR930701970A (ko) 1993-09-08
NO931580D0 (no) 1993-04-30
GR3022210T3 (en) 1997-04-30
ATE146971T1 (de) 1997-01-15
AU8758391A (en) 1992-05-26

Similar Documents

Publication Publication Date Title
GR3033144T3 (en) Methods for treating interleukin-1 and tumor necrosis factor mediated diseases.
FI881736A0 (fi) Olutmäskiuutteen käyttö kosmeettisten valmisteiden valmistukseen, kosmeettinen valmiste ja olutmäskiuute
ZA918712B (en) Pharmaceutical product comprising an antibody to tnf or a tnf binding fragment thereof and a xanthine derivative
NL194748B (nl) Osmotische doseringsvorm voor behandeling van cardiovasculaire ziekten.
ATE247974T1 (de) Kombinationtherapie mit einem tnf-bindendem protein zür behandlung von durch tnf verursachten erkrangungen
HUT70034A (en) Process for preparing pharmaceutical compositions containing dipyridamole for the treatment of proliferative diseases
WO1992012715A3 (fr) Emploi de loperamide et de composes apparentes dans le traitement de symptomes de maladies respiratoires
CA2273852A1 (fr) Therapie combinee utilisant un inhibiteur de l'il-1 pour traiter les maladies induites par l'il-1
MY111961A (en) Therapeutic method
DE69719754D1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
RU95111308A (ru) Производные 2-амино-4-фенил-4-оксомасляной кислоты, способы получения, фармацевтическая композиция
TW197423B (fr)
ATE202709T1 (de) Zusammensetzungen die g-csf und ein tnf- bindungsprotein enthalten
EP0417003A3 (en) Use of antiprogestomimetics for stimulating ovulation
AU1370088A (en) Use of antigenic substances for the prophylaxis or therapy of disorders and diseases within the gastrointestinal tract of animals and humans
Joosten et al. Synergistic protection against cartilage destruction by low dose prednisolone and interleukin-10 in established murine collagen arthritis
DE3371515D1 (en) Cycloalkyl derivatives of benzisoselenazolones, process for their preparation and pharmaceutical compositions containing them
DE59010302D1 (de) R-(-)-1-(5-Hydroxyhexyl)-3-methyl-7-propylxanthin, Verfahren zu dessen Herstellung und diese Verbindung enthaltende Arzneimittel
IE811612L (en) Thiazoles
Ancill et al. Oral caffeine augmentation of ECT.
DE3064854D1 (en) Quail-egg lyophilisate for the treatment of immuno-allergic diseases
WO1996020690A3 (fr) Monomeres de 3,3-(disubstitue)cyclohexan-1-ylidine acetate et composes apparentes
Manigand et al. Fingernail pigmentation in patients under cyclophosphamide and doxorubicine.
Platonov et al. Effect of thymosin fractions on the development of toxic swelling edema of the brain
EP1352656A3 (fr) Thérapie combinatoire utilisant une protèine de liaison du facteur de nécrose tumorale (TNF) dans le traitement de maladies induites par le TNF